Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines. Here we evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants who had received a two-dose regimen of CoronaVac, an inactivated vaccine used globally. We found that a heterologous CoronaVac prime vaccination of two doses followed by a BNT162b2 booster induces elevated virus-specific antibody levels and potent neutralization activity against the ancestral virus and the Delta variant, resembling the titers obtained after two doses of mRNA vaccines. Although neutralization of Omicron was undetectable in participants who had received a two-dose regimen of CoronaVac, the BNT162b2 booster resulted in a 1.4-fold increase in neutralization activity against Omicron compared with the two-dose mRNA vaccine. Despite this increase, neutralizing antibody titers were reduced by 7.1-fold and 3.6-fold for Omicron compared with the ancestral strain and the Delta variant, respectively. These findings have immediate implications for multiple countries that previously used a CoronaVac regimen and reinforce the idea that the Omicron variant is associated with immune escape from vaccines or infection-induced immunity, highlighting the global need for vaccine boosters to combat the impact of emerging variants.
Article activity feed
-
-
SciScore for 10.1101/2021.12.27.21268459: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics statement: This study was approved by the National Bioethics Committee of the Dominican Republic (CONABIOS).
Consent: Informed consent was obtained from all enrolled vaccinated.Sex as a biological variable not detected. Randomization not detected. Blinding ELISA and neutralizations were performed blinded. Power Analysis not detected. Cell Line Authentication Contamination: The cell line has been tested negative for contamination with mycoplasma. Table 2: Resources
Antibodies Sentences Resources Plates were washed three times with PBS-T (PBS with 0.1% Tween-20) and 50 μl of HRP anti-Human IgG Antibody (GenScript #A00166, 1:5,000) diluted in dilution solution added to each well. anti-Human IgGsug…SciScore for 10.1101/2021.12.27.21268459: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics statement: This study was approved by the National Bioethics Committee of the Dominican Republic (CONABIOS).
Consent: Informed consent was obtained from all enrolled vaccinated.Sex as a biological variable not detected. Randomization not detected. Blinding ELISA and neutralizations were performed blinded. Power Analysis not detected. Cell Line Authentication Contamination: The cell line has been tested negative for contamination with mycoplasma. Table 2: Resources
Antibodies Sentences Resources Plates were washed three times with PBS-T (PBS with 0.1% Tween-20) and 50 μl of HRP anti-Human IgG Antibody (GenScript #A00166, 1:5,000) diluted in dilution solution added to each well. anti-Human IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Briefly, 300 μl of serial fold virus dilutions were used to infect Vero E6 cells in MEM supplemented NaHCO3, 4% FBS 0.6% Avicel RC-581. Vero E6suggested: NoneSoftware and Algorithms Sentences Resources Health care worker (HCW) volunteers from the Yale New Haven Hospital (YNHH) were enrolled and included in this study (IRB Protocol ID 2000028924, approved by the Yale Human Research Protection Program Institutional Review Board. Yale Human Research Protection Programsuggested: NoneThe clinical data were collected using REDCap (v5.19.15 @2021 Vanderbilt University) software. REDCapsuggested: (REDCap, RRID:SCR_003445)Statistical analysis: All analyses of patient samples were conducted using GraphPad Prism 8.4.3 and JMP 15. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
